Ally Bridge Group expects its newest investment vehicle - an Asia-focused healthcare hedge fund - will have a surplus of buying opportunities given the plunge of the stock market in China. In other territories, such as Taiwan,...
...in Taiwan's technology and IT plays has come at biotech's expense. The meteoric rise of Taiwan biotech... ...down. That news was followed this spring by a report of clinical data by another Taiwan biotech...
The Daiwa Corporate Investment Co. Ltd. private equity arm of Daiwa Securities Group has for years made one-off investments in biotechs from its general funds. But the group decided a favorable investment climate for biotechs...
...it will surely expedite the clinical trial execution process, which will create another benefit for Taiwan biotech... ...structure infections (ABSSSIs). TaiGen has exclusive, worldwide rights to Taigexyn from Actavis plc (NYSE:ACT). The Taiwan biotech...
Ally Bridge Group expects its newest investment vehicle - an Asia-focused healthcare hedge fund - will have a surplus of buying opportunities given the plunge of the stock market in China. In other territories, such as Taiwan,...
...in Taiwan's technology and IT plays has come at biotech's expense. The meteoric rise of Taiwan biotech... ...down. That news was followed this spring by a report of clinical data by another Taiwan biotech...
The Daiwa Corporate Investment Co. Ltd. private equity arm of Daiwa Securities Group has for years made one-off investments in biotechs from its general funds. But the group decided a favorable investment climate for biotechs...
...it will surely expedite the clinical trial execution process, which will create another benefit for Taiwan biotech... ...structure infections (ABSSSIs). TaiGen has exclusive, worldwide rights to Taigexyn from Actavis plc (NYSE:ACT). The Taiwan biotech...
